Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 24 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Nectar Lifescience Ltd

About the Company - Nectar Lifescience Ltd

No data availabale for About the Company
INDUSTRYADDRESSCONTACT
Industry not foundAddress not foundContact not found
Management Data not Available

Basic Stock Data of Nectar Lifescience Ltd

Market Cap 906 Cr.
Current Price 40.4
High / Low45.7/14.4
Stock P/E112
Book Value 47.6
Dividend Yield0.00 %
ROCE0.18 %
ROE6.01 %
Face Value 1.00

Data Source: screener.in

Competitors of Nectar Lifescience Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Ortin Laboratories Ltd 16.8 Cr. 20.730.4/16.2 12.00.00 %1.80 %0.64 % 10.0
Astrazeneca Pharma India Ltd 13,758 Cr. 5,5037,221/3,09886.3 2620.29 %30.9 %23.0 % 2.00
RPG Life Sciences Ltd 2,692 Cr. 1,6281,740/64631.7 2030.72 %33.2 %24.2 % 8.00
J B Chemicals & Pharmaceuticals Ltd 25,702 Cr. 1,6571,940/87550.0 1750.52 %22.4 %17.6 % 1.00
Caplin Point Laboratories Ltd 11,887 Cr. 1,5651,619/57527.2 2730.28 %26.3 %25.6 % 2.00
Industry Average13.56 Cr5.7439.041850.36%22.92%18.21%4.6

Nectar Lifescience Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales427.97378.00348.78385.06364.57443.01476.24403.03388.65344.13388.81394.13397.97
Expenses396.50345.25319.55349.69337.11396.43427.09361.21396.05342.69370.72358.59371.11
Operating Profit31.4732.7529.2335.3727.4646.5849.1541.82-7.401.4418.0935.5426.86
OPM %7.35%8.66%8.38%9.19%7.53%10.51%10.32%10.38%-1.90%0.42%4.65%9.02%6.75%
Other Income0.530.66-24.295.155.100.530.520.3610.7113.2417.920.4710.61
Interest27.8830.6325.6525.7518.0117.6217.4321.3720.9917.4619.6617.6220.52
Depreciation15.0915.1015.0114.2814.1514.2814.2614.7014.7914.7814.8515.3315.31
Profit before tax-10.97-12.32-35.720.490.4015.2117.986.11-32.47-17.561.503.061.64
Tax %33.36%34.50%-14.73%-265.31%-367.50%36.09%35.15%36.17%30.80%47.10%-144.67%40.52%38.41%
Net Profit-7.31-8.07-40.971.791.869.7311.663.90-22.47-9.293.681.821.02
EPS in Rs-0.33-0.36-1.830.080.080.430.520.17-1.00-0.410.160.080.05

Nectar Lifescience Ltd Quarterly Chart

Nectar Lifescience Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales1,3121,6221,6341,6381,6741,6351,8742,7792,3631,5411,6651,5201,525
Expenses1,0621,3321,3451,3711,4361,4111,6382,5142,1431,4321,5071,4671,443
Operating Profit2502902892672392242362642201091595382
OPM %19%18%18%16%14%14%13%10%9%7%10%3%5%
Other Income12161220623664-22114342
Interest115115138126123117115148126112797975
Depreciation61768477576264636160575960
Profit before tax8511578856467635937-8534-42-11
Tax %14%25%21%22%15%18%17%19%15%14%26%43%
Net Profit738662665455524832-7325-24-3
EPS in Rs3.263.822.772.952.422.472.332.121.42-3.271.12-1.08-0.12
Dividend Payout %3%3%4%3%4%2%2%2%4%0%0%0%

Nectar Lifescience Ltd Profit & Loss Yearly Chart

Nectar Lifescience Ltd Growth

Compounded Sales Growth
10 Years:-1%
5 Years:-4%
3 Years:-14%
TTM:1%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:%
TTM:150%
Stock Price CAGR
10 Years:11%
5 Years:21%
3 Years:29%
1 Year:153%
Return on Equity
10 Years:3%
5 Years:0%
3 Years:-3%
Last Year:-6%

Nectar Lifescience Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital22222222222222222222222222
Reserves7628459059369329841,0361,0831,1141,0401,0651,0421,045
Borrowings1,043879858925962878955903779903860754681
Other Liabilities293527609628640696710696718423443371394
Total Liabilities2,1212,2742,3942,5102,5562,5812,7242,7052,6332,3882,3912,1892,143
Fixed Assets858914948934906881852825785772723662826
CWIP150139122919910210010011599857878
Investments0001111101111
Other Assets1,1131,2211,3241,4851,5511,5971,7711,7801,7331,5171,5821,4491,239
Total Assets2,1212,2742,3942,5102,5562,5812,7242,7052,6332,3882,3912,1892,143

Nectar Lifescience Ltd Reserves and Borrowings Chart

Nectar Lifescience Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 165361255144169199652392852195134
Cash from Investing Activity -234-99-90-60-77-18-29-26-33-291752
Cash from Financing Activity 62-282-161-61-89-204-40-201-25211-119-186
Net Cash Flow-7-204233-23-412-04-8-0

Nectar Lifescience Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days857984991071121197361899867
Inventory Days238216240253260270226151192185197212
Days Payable7812213914615416714280104108112100
Cash Conversion Cycle244172185207213215203145150166182179
Working Capital Days190137152173178186190129149190198204
ROCE %13%13%12%11%10%10%9%10%8%3%5%-0%

Nectar Lifescience Ltd Financial Efficiency Indicators Chart

Nectar Lifescience Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Promoters55.80%55.80%55.80%55.80%55.80%55.80%55.80%55.80%55.80%55.80%55.80%55.80%
FIIs2.62%2.62%2.62%2.46%1.52%1.67%1.49%16.12%15.99%16.07%16.00%16.02%
Government0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.02%0.02%0.02%0.02%0.02%
Public41.58%41.58%41.58%41.74%42.68%42.53%42.72%28.06%28.20%28.12%28.18%28.17%
No. of Shareholders46,73847,39453,30455,12456,07364,01263,90962,94064,42262,87461,58260,283

Nectar Lifescience Ltd Shareholding Pattern Chart

No. of Nectar Lifescience Ltd Shareholders

This stock is not held by any mutual fund

Nectar Lifescience Ltd ROCE Trend

Nectar Lifescience Ltd EPS Trend

Nectar Lifescience Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue1.001.001.001.001.00
Basic EPS (Rs.)-1.081.12-3.271.422.12
Diluted EPS (Rs.)-1.081.12-3.271.422.12
Cash EPS (Rs.)1.563.66-0.584.134.94
Book Value[Excl.RevalReserv]/Share (Rs.)47.4748.5147.3650.6649.28
Book Value[Incl.RevalReserv]/Share (Rs.)47.4748.5147.3650.6649.28
Revenue From Operations / Share (Rs.)67.9474.4268.82105.52124.09
PBDIT / Share (Rs.)4.297.575.039.9912.05
PBIT / Share (Rs.)1.655.032.347.289.23
PBT / Share (Rs.)-1.891.52-3.781.672.62
Net Profit / Share (Rs.)-1.081.12-3.271.422.12
NP After MI And SOA / Share (Rs.)-1.081.12-3.271.422.12
PBDIT Margin (%)6.3110.177.319.469.70
PBIT Margin (%)2.436.763.406.907.43
PBT Margin (%)-2.782.04-5.491.582.11
Net Profit Margin (%)-1.581.50-4.741.341.71
NP After MI And SOA Margin (%)-1.581.50-4.741.341.71
Return on Networth / Equity (%)-2.272.30-6.892.794.30
Return on Capital Employeed (%)2.858.134.0911.7814.72
Return On Assets (%)-1.101.04-2.961.201.75
Long Term Debt / Equity (X)0.210.260.120.100.14
Total Debt / Equity (X)0.700.790.790.650.72
Asset Turnover Ratio (%)0.660.680.600.881.03
Current Ratio (X)1.591.561.041.291.28
Quick Ratio (X)0.620.690.540.510.57
Inventory Turnover Ratio (X)1.391.651.131.942.51
Dividend Payout Ratio (NP) (%)0.000.00-1.533.522.83
Dividend Payout Ratio (CP) (%)0.000.00-8.611.211.21
Earning Retention Ratio (%)0.000.00101.5396.4897.17
Cash Earning Retention Ratio (%)0.000.00108.6198.7998.79
Interest Coverage Ratio (X)1.212.161.011.781.82
Interest Coverage Ratio (Post Tax) (X)0.691.320.571.251.32
Enterprise Value (Cr.)1091.931381.461231.83941.691163.72
EV / Net Operating Revenue (X)0.710.820.790.390.41
EV / EBITDA (X)11.358.1310.924.204.31
MarketCap / Net Operating Revenue (X)0.230.320.270.090.13
Retention Ratios (%)0.000.00101.5396.4797.16
Price / BV (X)0.330.490.390.190.34
Price / Net Operating Revenue (X)0.230.320.270.090.13
EarningsYield-0.060.04-0.170.140.12

Nectar Lifescience Ltd Profitability Ratios (%)

Nectar Lifescience Ltd Liquidity Ratios

Nectar Lifescience Ltd Liquidity Ratios (%)

Nectar Lifescience Ltd Interest Coverage Ratios (%)

Nectar Lifescience Ltd Valuation Ratios

Fair Value of Nectar Lifescience Ltd Stock

Fair Value: ₹326.81

The stock is undervalued by 708.94% compared to the current price ₹40.4

*Investments are subject to market risks

Strength and Weakness of Nectar Lifescience Ltd Stock

StrengthWeakness
  1. The company has higher reserves (983.77 cr) compared to borrowings (875.38 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (1.15 cr) and profit (42.23 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 5.11 and average Dividend Yield of 5.38%.
  2. The stock has a low average ROCE of 8.67%, which may not be favorable.
  3. The stock has a high average Working Capital Days of 173.00, which may not be favorable.
  4. The stock has a high average Cash Conversion Cycle of 188.42, which may not be favorable.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Nectar Lifescience Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE